強直性脊椎炎市場：薬物クラス（NSAIDs、TNF阻害剤、その他）、流通チャネル（病院薬局、小売店薬局、オンライン薬局）別。世界の機会分析および産業予測、2021-2030年

Ankylosing Spondylitis Market by Drug Class (NSAIDs, TNF Inhibitors and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021–2030

強直性脊椎炎市場は、2020年には51億4094万ドルで、2021年から2030年にかけてCAGR4.6%を記録し、2030年には81億1559万ドルに達すると予測されています。強直性脊椎炎（AS）は、患者の脊椎に痛みやこわばりを生... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年1月1日	US$6,168 シングルユーザーライセンスライセンス・価格情報・注文方法はこちら	220	英語

サマリー

強直性脊椎炎市場は、2020年には51億4094万ドルで、2021年から2030年にかけてCAGR4.6%を記録し、2030年には81億1559万ドルに達すると予測されています。
強直性脊椎炎（AS）は、患者の脊椎に痛みやこわばりを生じさせるまれなタイプの関節炎です。この生涯続く疾患は、ベヒテロウ病としても知られ、通常、患者の腰部から始まります。首まで広がったり、体の他の部分の関節に損傷を与えることもあります。強直性脊椎炎の症状としては、腰痛や肩こり、股関節痛、関節痛、首痛、呼吸困難、疲労、食欲不振、原因不明の体重減少、腹痛、下痢などがあります。強直性脊椎炎の原因は特定されていませんが、遺伝的な要因が関与しているようです。特に、HLA-B27という遺伝子を持っている人は、強直性脊椎炎を発症するリスクが非常に高くなります。しかし、この遺伝子を持つ人のうち、発症するのは一部の人だけです。強直性脊椎炎は、背中や骨盤のX線検査、あるいは身体検査で診断することができます。
強直性脊椎炎の治療薬は、まだ市販されていません。利用可能な治療法は、主に強直性脊椎炎によって引き起こされる不快感を軽減するのに役立ちます。様々な治療の選択肢は、演習、薬物や手術が含まれています。強直性脊椎炎の治療には、メトトレキサートなどの疾患修飾性抗リウマチ薬（DMARDs）、イブプロフェン、ナプロキセン、アスピリンなどの非ステロイド性抗炎症薬（NSAIDs）、エンブレル、フミラ、シムジア、レミケードなどの生物製剤など様々な薬剤が使用されています。強直性脊椎炎に伴う激しい痛みや炎症の治療に時折使用されるプレドニゾロンなどのコルチコステロイド。
強直性脊椎炎の有病率の増加は、世界的に、強直性脊椎炎市場の成長を駆動します。例えば、世界保健機関（WHO）の報告によると、2021年には、世界中で約17億1千万人が筋骨格系疾患を患っています。また、人々の強直性脊椎炎に関する認知度の向上は、強直性脊椎炎市場の成長を促進します。また、メーカーや研究者による強直性脊椎炎の治療に関する研究開発が、市場の成長に寄与しています。さらに、強直性脊椎炎患者の治療やライフスタイルの改善に関する各国政府の取り組みが、市場の成長を後押ししています。また、病院数の増加や整備された医療インフラも、市場の成長に寄与しています。しかし、治療費の高騰や強直性脊椎炎に関する人々の認識不足が、市場の成長を制限する可能性があります。
強直性脊椎炎分野における治療法の進歩や研究開発活動は、市場の成長を後押ししています。例えば、2020年11月、コセンティクス（セクキヌマブ）は、1回の注射で300mgの投与を可能にする新しい300mg自動注射器およびプレフィルドシリンジの欧州委員会（EC）の承認を取得しました。さらに、新製品の承認・上市も市場の成長に寄与しています。例えば、バイオ医薬品の世界的な開発・製造企業であるイーライリリー・アンド・カンパニーは、2019年8月に「タルツ（イキセキズマブ）」の「活動性強直性脊椎炎治療薬」の承認を取得した。
強直性脊椎炎市場は、薬物クラス、流通チャネル、地域に基づいてセグメント化されています。ドラッグクラス別では、NSAIDs、TNF阻害剤、その他に分類されます。流通経路別では、病院薬局、小売薬局、オンライン薬局に区分されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAに分析しています。
本レポートで紹介する主要企業は、AbbVie, Inc.、Amgen, Inc.、Pfizer, Inc.、Novartis AG、Eli Lilly and Company、UCB、Gilead Sciences、Reliance Life Sciences Pvt. Ltd、Janssen Pharmaceuticals、Merck & Co., Inc.などです。Inc.が含まれています。

ステークホルダーにとっての主なメリット

本レポートでは、世界の強直性脊椎炎の市場規模を現在の動向と将来の予測とともに詳細に分析し、差し迫った投資ポケットを解明します。
2021年から2030年までの市場分析を提供しており、利害関係者が市場に存在する機会を活用することを可能にすると期待されます。
地域の包括的な分析は、地域市場を理解し、戦略的な事業計画を促進し、優勢な機会を決定するのに役立ちます。
主要企業のプロファイルと成長戦略は、世界の強直性脊椎炎市場成長の競争的展望を理解するために徹底的に分析されています。

主要な市場セグメント
# 薬物クラス別
#NSAIDs（非ステロイド性抗炎症薬
#TNF阻害剤
##その他
#販売チャネル別
##病院薬局
##小売店
##オンライン薬局

#地域別
##北アメリカ
###アメリカ
###カナダ
###メキシコ

##ヨーロッパ
###ドイツ
###フランス
###イギリス
###イタリア
###スペイン
###その他のヨーロッパ

##アジア太平洋地域
###日本
###中国
###オーストラリア
###インド
###韓国
###その他のアジア太平洋地域

#ラメア
###ブラジル
###サウジアラビア
###南アフリカ
###LAMEAの他の地域

主要な市場関係者
アッヴィー社
アムジェン、Inc,
イーライリリー・アンド・カンパニー
ギリアド・サイエンス
ヤンセン・ファーマシューティカルズ
メルク・アンド・カンパニーInc.
ノバルティスAG
ファイザー株式会社
リライアンス・ライフサイエンス社
UCB, Inc,

ページTOPに戻る

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of ankylosing spondylitis
3.5.1.2.Rise in number of hospitals and diagnostic centers
3.5.1.3.Advancements in the ankylosing spondylitis treatment

3.5.2.Restraint

3.5.2.1.High cost of treatment and lack of awareness
3.5.2.2.Adverse effect of long-term use of drug therapy

3.5.3.Opportunity

3.5.3.1.Advancements in treatment of ankylosing spondylitis.

3.5.4.Impact analysis

3.6.Impact analysis of COVID-19 on the ankylosing spondylitis market

CHAPTER 4:ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.Nonsteroidal anti-inflammatory drugs (NSAIDs)

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.TNF inhibitors

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Others

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

CHAPTER 5:ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital pharmacy

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Retail pharmacy

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Online pharmacy

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:ANKYLOSING SPONDYLITIS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America Ankylosing spondylitis market, by Drug Class
6.2.3.North America Ankylosing spondylitis market, by Distribution channel
6.2.4.Market size and forecast, by country

6.2.4.1.U.S.

6.2.4.1.1.U.S. Ankylosing spondylitis market, by Drug Class
6.2.4.1.2.U.S. Ankylosing spondylitis market, by Distribution channels

6.2.4.2.Canada

6.2.4.2.1.Canada ankylosing spondylitis market, by Drug Class
6.2.4.2.2.Canada Ankylosing spondylitis market, by Distribution channels

6.2.4.3.Mexico

6.2.4.3.1.Mexico ankylosing spondylitis market, by Drug Class
6.2.4.3.2.Mexico ankylosing spondylitis market, by Distribution channels

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe Ankylosing spondylitis market, by Drug Class
6.3.3.Europe Ankylosing spondylitis market, by Distribution channel
6.3.4.Market size and forecast, by country

6.3.4.1.Germany

6.3.4.1.1.Germany ankylosing spondylitis market, by Drug Class
6.3.4.1.2.Germany ankylosing spondylitis market, by Distribution channels

6.3.4.2.France

6.3.4.2.1.France ankylosing spondylitis market, by Drug Class
6.3.4.2.2.France ankylosing spondylitis market, by Distribution channels

6.3.4.3.UK

6.3.4.3.1.UK ankylosing spondylitis market, by Drug Class
6.3.4.3.2.UK ankylosing spondylitis market, by Distribution channels

6.3.4.4.Italy

6.3.4.4.1.Italy ankylosing spondylitis market, by Drug Class
6.3.4.4.2.Italy ankylosing spondylitis market, by Distribution channels

6.3.4.5.Spain

6.3.4.5.1.Spain ankylosing spondylitis market, by Drug Class
6.3.4.5.2.Spain ankylosing spondylitis market, by Distribution channels

6.3.4.6.Rest of Europe

6.3.4.6.1.Rest of Europe ankylosing spondylitis market, by Drug Class
6.3.4.6.2.Rest of Europe ankylosing spondylitis market, by Distribution channels

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific Ankylosing spondylitis market, by Drug Class
6.4.3.Asia-Pacific Ankylosing spondylitis market, by Distribution channel
6.4.4.Market size and forecast, by country

6.4.4.1.Japan

6.4.4.1.1.Japan ankylosing spondylitis market, by Drug Class
6.4.4.1.2.Japan ankylosing spondylitis market, by Distribution channels

6.4.4.2.China

6.4.4.2.1.China ankylosing spondylitis market, by Drug Class
6.4.4.2.2.China ankylosing spondylitis market, by Distribution channels

6.4.4.3.Australia

6.4.4.3.1.Australia ankylosing spondylitis market, by Drug Class
6.4.4.3.2.Australia ankylosing spondylitis market, by Distribution channels

6.4.4.4.India

6.4.4.4.1.India ankylosing spondylitis market, by Drug Class
6.4.4.4.2.India ankylosing spondylitis market, by Distribution channels

6.4.4.5.South Korea

6.4.4.5.1.South Korea ankylosing spondylitis market, by Drug Class
6.4.4.5.2.South Korea ankylosing spondylitis market, by Distribution channels

6.4.4.6.Rest of Asia-Pacific

6.4.4.6.1.Rest of Asia-Pacific ankylosing spondylitis market, by Drug Class
6.4.4.6.2.Rest of Asia-Pacific ankylosing spondylitis market, by Distribution channels

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA Ankylosing spondylitis market, by Drug Class
6.5.3.LAMEA Ankylosing spondylitis market, by Distribution channel
6.5.4.Market size and forecast, by country

6.5.4.1.Brazil

6.5.4.1.1.Brazil ankylosing spondylitis market, by Drug Class
6.5.4.1.2.Brazil ankylosing spondylitis market, by Distribution channels

6.5.4.2.Saudi Arabia

6.5.4.2.1.Saudi Arabia ankylosing spondylitis market, by Drug Class
6.5.4.2.2.Saudi Arabia ankylosing spondylitis market, by Distribution channels

6.5.4.3.South Africa

6.5.4.3.1.South Africa ankylosing spondylitis market, by Drug Class
6.5.4.3.2.South Africa ankylosing spondylitis market, by Distribution channels

6.5.4.4.Rest of LAMEA

6.5.4.4.1.Rest of LAMEA ankylosing spondylitis market, by Drug Class
6.5.4.4.2.Rest of LAMEA ankylosing spondylitis market, by Distribution channels

CHAPTER 7:COMPANY PROFILES

7.1.AbbVie, Inc

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.Amgen Inc.

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments

7.3.Eli Lilly and Company

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments

7.4.Gilead Sciences

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.Johnson & Johnson (Janssen)

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.Merck & Co. Inc

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.Novartis AG

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance

7.8.Pfizer Inc.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.Reliance Life Sciences Pvt. Ltd

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio

7.10.UCB, Inc.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio

List of Tables

LIST OF TABLES

TABLE 01.ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 02.ANKYLOSING SPONDYLITIS MARKET BY DRUG CLASS, FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2020–2030 ($MILLION)
TABLE 03.ANKYLOSING SPONDYLITIS MARKET BY DRUG CLASS, FOR TNF INHIBITORS, BY REGION, 2020–2030 ($MILLION)
TABLE 04.ANKYLOSING SPONDYLITIS MARKET BY DRUG CLASS, FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 05.ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 06.ANKYLOSING SPONDYLITIS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2020-2030 ($MILLION)
TABLE 07.ANKYLOSING SPONDYLITIS MARKET FOR RETAIL PHARMACY, BY REGION, 2020-2030 ($MILLION)
TABLE 08.ANKYLOSING SPONDYLITIS MARKET FOR ONLINE PHARMACY, BY REGION, 2020-2030 ($MILLION)
TABLE 09.ANKYLOSING SPONDYLITIS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 10.NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 11.NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 12.NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET WAS VALUED, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 13.U.S. ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 14.U.S. ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 15.CANADA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 16.CANADA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 17.MEXICO ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 18.MEXICO ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 19.EUROPE ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 20.EUROPE ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 21.EUROPE ANKYLOSING SPONDYLITIS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 22.GERMANY ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 23.GERMANY ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 24.FRANCE ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 25.FRANCE ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 26.UK ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 27.UK ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 28.ITALY ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 29.ITALY ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 30.SPAIN ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 31.SPAIN ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 32.REST OF EUROPE ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 33.REST OF EUROPE ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 34.ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 35.ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 36.ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 37.JAPAN ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 38.JAPAN ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 39.CHINA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 40.CHINA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 41.AUSTRALIA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 42.AUSTRALIA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 43.INDIA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 44.INDIA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 45.SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 46.SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 47.REST OF ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 49.LAMEA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 50.LAMEA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 51.LAMEA ANKYLOSING SPONDYLITIS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 52.BRAZIL ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 53.BRAZIL ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 54.SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 55.SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 56.SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 57.SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 58.REST OF LAMEA ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 59.REST OF LAMEA ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNELS, 2020-2030 ($MILLION)
TABLE 60.ABBVIE : COMPANY SNAPSHOT
TABLE 61.ABBVIE: OPERATING SEGMENTS
TABLE 62.ABBVIE: PRODUCT PORTFOLIO
TABLE 63.AMGEN: COMPANY SNAPSHOT
TABLE 64.AMGEN: OPERATING SEGMENTS
TABLE 65.AMGEN: PRODUCT PORTFOLIO
TABLE 66.LILLY: COMPANY SNAPSHOT
TABLE 67.LILLY: OPERATING SEGMENTS
TABLE 68.LILLY: PRODUCT PORTFOLIO
TABLE 69.GILEAD: COMPANY SNAPSHOT
TABLE 70.GILEAD: OPERATING SEGMENTS
TABLE 71.GILEAD: PRODUCT PORTFOLIO
TABLE 72.JANSSEN: COMPANY SNAPSHOT
TABLE 73.JANSSEN: OPERATING SEGMENTS
TABLE 74.JANSSEN: PRODUCT PORTFOLIO
TABLE 75.MERCK: COMPANY SNAPSHOT
TABLE 76.MERCK: OPERATING SEGMENTS
TABLE 77.MERCK: PRODUCT PORTFOLIO
TABLE 78.NOVARTIS: COMPANY SNAPSHOT
TABLE 79.NOVARTIS: OPERATING SEGMENTS
TABLE 80.NOVARTIS: PRODUCT PORTFOLIO
TABLE 81.PFIZER: COMPANY SNAPSHOT
TABLE 82.PFIZER: OPERATING SEGMENTS
TABLE 83.PFIZER: PRODUCT PORTFOLIO
TABLE 84.RELIANCE: COMPANY SNAPSHOT
TABLE 85.RELIANCE: OPERATING SEGMENTS
TABLE 86.RELIANCE: PRODUCT PORTFOLIO
TABLE 87.UCB: COMPANY SNAPSHOT
TABLE 88.UCB: OPERATING SEGMENTS
TABLE 89.UCB: PRODUCT PORTFOLIO

List of Figures

LIST OF FIGURES

FIGURE 01.ANKYLOSING SPONDYLITIS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 06.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTES
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.MODERATE INTENSITY OF RIVALRY
FIGURE 12.TOP PLAYER POSITIONING, 2020
FIGURE 13.IMPACT ANALYSIS
FIGURE 14.COMPARATIVE ANALYSIS OF ANKYLOSING SPONDYLITIS MARKET BY DRUG CLASS, FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF ANKYLOSING SPONDYLITIS MARKET BY DRUG CLASS, FOR TNF INHIBITORS, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ANKYLOSING SPONDYLITIS MARKET BY DRUG CLASS, FOR OTHERS, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF ANKYLOSING SPONDYLITIS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF ANKYLOSING SPONDYLITIS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF ANKYLOSING SPONDYLITIS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 21.ABBVIE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 22.ABBVIE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 23.AMGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.AMGEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 25.AMGEN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 26.LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.LILLY: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28.LILLY: REVENUE SHARE BY REGION, 2020(%)
FIGURE 29.GILEAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.GILEAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.GILEAD: REVENUE SHARE BY REGION, 2020(%)
FIGURE 32.JANSSEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.JANSSEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.JANSSEN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 35.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 38.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.NOVARTIS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 41.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.PFIZER: REVENUE SHARE BY REGION, 2020(%)

ページTOPに戻る

Table of Contents

Summary

The ankylosing spondylitis market was valued at $5,140.94 million in 2020, and is projected to reach $8,110.59 million by 2030, registering a CAGR of 4.6%% from 2021 to 2030.
Ankylosing spondylitis (AS) is a rare type of arthritis that causes pain and stiffness in patient’s spine. This lifelong condition, also known as bechterew’s disease, usually starts in lower back of patients. It can spread up to neck or damage joints in other parts of body. The symptoms of ankylosing spondylitis include, lower back pain and stiffness, hip pain, joint pain, neck pain, difficulty breathing, fatigue, loss of appetite and unexplained weight loss, abdominal pain and diarrhea. Ankylosing spondylitis has no known specific cause, though genetic factors seem to be involved. In particular, people who have a gene called HLA-B27 are at a greatly increased risk of developing ankylosing spondylitis. However, only some people with the gene develop the condition. Ankylosing spondylitis can be diagnosed via X-rays of the back and pelvis; or by physical examination.
The cure for ankylosing spondylitis is still not available on the market. The available treatments mainly help reduce the discomfort caused by ankylosing spondylitis. Various treatment options include, the exercises, medications and surgery. Various medications are used for ankylosing spondylitis treatment such as disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, and aspirin; and biologics, such as enbrel, humira, cimzia and remicade. Corticosteroids such as prednisolone used occasionally to treat severe pain and inflammation associated with ankylosing spondylitis.
The increase in prevalence of ankylosing spondylitis worldwide, drive the growth of ankylosing spondylitis market. For instance, according to report of World Health Organization (WHO), in 2021, approximately 1.71 billion people had musculoskeletal conditions worldwide. In addition, increase in awareness about the ankylosing spondylitis in people propels the growth of ankylosing spondylitis market. The R&D in the treatment of the ankylosing spondylitis by the manufacturers and researchers have contributed in the growth of market. Furthermore, initiatives taken by the respective governments to treat and improve lifestyle of ankylosing spondylitis patients have boost the market growth. The rise in number of hospitals and well-developed healthcare infrastructure further contributes in market growth. However, the high cost of treatment and lack of awareness in people about ankylosing spondylitis may limit the growth of market.
Advancement in the therapy and R&D activity in ankylosing spondylitis sector boosts the growth of market. For instance, in November 2020, Cosentyx (secukinumab) received European commission (EC) approval for a new 300mg autoinjector and pre-filled syringe, which enable the 300mg dose to be administered in a single injection. Furthermore, new products approval and launch contribute toward the market growth. For instance, Eli Lilly and Company, a global developer and manufacturer of biopharmaceuticals, in August 2019, received approval for Taltz (ixekizumab) for the Treatment of Active Ankylosing Spondylitis.
The ankylosing spondylitis market is segmented on the basis of drug class, distribution channel and region. By drug class, the market is divided into NSAIDs, TNF inhibitors and others. By distribution channel, the market is divided into hospitals pharmacy, retail pharmacy, and online pharmacy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include AbbVie, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Eli Lilly and Company, UCB, Inc., Gilead Sciences, Reliance Life Sciences Pvt. Ltd, Janssen Pharmaceuticals, and Merck & Co. Inc.

KEY BENEFITS FOR STAKEHOLDERS

 The report provides an in-depth analysis of the global ankylosing spondylitis market size along with the current trends and future estimations to elucidate the imminent investment pockets.
 It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
 A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
 The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global ankylosing spondylitis market growth.

KEY MARKET SEGMENTS
# By Drug Class
##NSAIDs
##TNF inhibitors
##Others
#By Distribution Channel
##Hospital pharmacy
##Retail pharmacy
##Online pharmacy

#By Region
##North America
###U.S.
###Canada
###Mexico

##Europe
###Germany
###France
###UK
###Italy
###Spain
###Rest of Europe

##Asia Pacific
###Japan
###China
###Australia
###India
###South Korea
###Rest of Asia Pacific

##LAMEA
###Brazil
###Saudi Arabia
###South Africa
###Rest of LAMEA

KEY MARKET PLAYERS
 AbbVie, Inc.,
 Amgen, Inc.,
 Eli Lilly and Company
 Gilead Sciences
 Janssen Pharmaceuticals
 Merck & Co. Inc.
 Novartis AG,
 Pfizer, Inc.
 Reliance Life Sciences Pvt. Ltd
 UCB, Inc.,

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（通信回線）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（hospital）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

強直性脊椎炎市場：薬物クラス（NSAIDs、TNF阻害剤、その他）、流通チャネル（病院薬局、小売店薬局、オンライン薬局）別。世界の機会分析および産業予測、2021-2030年

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（通信回線）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（hospital）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?